Media Details

  • Home
  • Media
  • Details
  2021-01-04 07:17:26

POTENTIAL COLLABORATION OF EBI & BIONET-ASIA ON SARS-COV-2 VACCINE SUPPLY

KUALA LUMPUR, 4 JANUARY 2021 - Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601) through its wholly-owned subsidiary HWGB Biotech Sdn Bhd’s (“HWGB Biotech”) joint venture partner, US-based E-MO Biology Inc. (“EBI”), signed a letter of interest with Bionet-Asia Co. Ltd (“BNA” or the “Company”) for a potential collaboration on a vaccine supply whereby BNA will arrange the manufacturing and supply Bivalent Oral Poliomyelitis Vaccine Type I and III to EBI for the purpose of conducting phase IV clinical trial in relation to the COVID-19 pandemic in Malaysia.
 
BNA is a Thai-French privately-held biotech company focusing on the discovery, manufacturing, and supply of life-saving vaccines with a manufacturing base in Asia while their clinical and business operations have presence in Europe, Asia, and Australia. The company is leading the innovation in the pertussis field by improving pertussis vaccines using recombinant DNA technology.
 
BNA is also building unique expertise in genetic engineering, protein conjugation, cell culture, and vaccine formulation. The company has developed a broad pipeline with ten products in R&D and clinical stages, including vaccines and recombinant proteins such as CRM197 protein carrier, dengue, and hepatitis B vaccines. The company has been provided with technology to produce Hib meningitis vaccine which is now commercialized as a pentavalent vaccine in Asia.
 
Managing Director of EBI, Dr. Xie QiYi, said: “As we are intending to understand more on the vaccines and if any possible side effect on the subject on a larger scale, BNA vaccine supply will aid us immensely in the phase IV clinical trial. Thus we are able to move in the right direction to provide a safe, affordable, effective and easily administered vaccine to the public as soon as possible”.



Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare-related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; Trading of wires and cables; and travel agent and tour related services.


HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the distribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.
 
For more information about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, Facebook, LinkedIn, and Telegram to view the latest updates about our company ventures in the healthcare industry.


BioNet is a Thai-French privately-held biotech company focusing on the discovery, manufacturing and supply of life-saving vaccines with a manufacturing base in Asia and with clinical and business operations in Europe, Asia and Australia. BioNet is leading the innovation in the pertussis field by improving pertussis vaccines using recombinant DNA technology. In its state-of-the-art vaccine plant in Thailand, BioNet is also building a unique expertise in genetic engineering, protein conjugation, cell-culture and vaccine formulation. The company has developed a broad pipeline with ten products in R&D and clinical stages, including vaccines and recombinant proteins such as CRM197 protein carrier, dengue and hepatitis B vaccines.


Please refer to the US Food and Drug Administration website for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375
 
E-Mo Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Dr. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.

 



Back
image